奥齿泰(048260.KQ)：昨复牌，2022销售目标 1万亿韩元

韩国最大的种植牙造商奥齿泰(Osstem Implant)，于昨日(5月4日)复牌，截至目前其每股收报11.33万港元，较其停牌时的价格14.27万韩元，下跌20.6%。

奥齿泰也公布其2022年第一季业绩，其2022年销售目标为1万亿韩元。

以下来自google翻译：

OsstemImplant第一季度表现良好，股票再次开始交易 

由于强劲的海外增长，韩国最大的牙科植入物制造商奥齿泰(Osstem Implant)2022年度第一季度的营业利润创纪录。

根据周三发布的公告，奥齿泰第一季度的营业利润为512亿韩元(4070万美元)，同比增长100%。

第一季度销售额为2341亿韩元，同比增长36%。该季度的净利润没有披露。

第一季度销售额创历史新高。

OsstemImplant因其强劲的销售而在海外实现了快速增长。该公司第一季度的海外销售额为1680亿韩元，同比增长58%。据该公司称，季度销售额在中国增长了56%，在俄罗斯增长了59%，在美国增长了76%。 

去年1月3日，该公司报告称，其财务部经理在2020年11月至2021年10月期间的15次交易中从公司账户中提取了总计2215亿韩元。OsstemImplant股票在Kosaq暂停交易、恢复交易。韩国交易所的企业审查委员会决定不让该公司退市。

OsstemImplant周三召开紧急董事会会议，决定购买其价值300亿美元的股票。

“在这次挪用公款事件之后，我们将改善内部稳定性并加快我们的全球业务计划，”首席执行官Um Tae-kwan说。

Um 承诺通过“实施各种有利于股东的政策”来增加股东价值，首先是回购股票。 

挪用公款后，Osstem Implant采取措施防止此类事件在未来再次发生并提高其业务诚信，例如将超过一半的董事会成员任命为非执行董事，并成立企业审计委员会和道德管理委员会，公司说。它还任命了一名合规官，并成立了一个委员会，负责推荐非执行董事。

OsstemImplant今年的销售目标是1万亿韩元，比去年的8230亿韩元增长21.5%，营业利润目标是1700亿韩元。2021年公司营业利润为1419亿韩元。

Osstem Implant has good Q1, shares start trading again

Osstem Implant, the country’s largest dental implant manufacturer, reported record operating profit for the first quarter thanks to the strong overseas growth. 
The company reported first quarter operating profit of 51.2 billion won ($40.7 million), up 100 percent on year, according to an earnings announcement released Wednesday.  
Quarterly sales were 234.1 billion won, a 36 percent increase on year. Net profit for the quarter was not disclosed. 
The sales were a record high for a first quarter. 

Osstem Implant cited rapid growth overseas for its strong sales. The company had overseas sales of 168 billion won in the first quarter, up 58 percent year on year.  
According to the company, quarterly sales grew by 56 percent in China, 59 percent in Russia and 76 percent in the United States. 
Last Jan. 3, the company reported that the manager of its finance department skimmed a total of 221.5 billion won from the company’s accounts in 15 transactions between Nov. 2020 and Oct. 2021. Trading in Osstem Implant shares were suspended and resumed on the Kosaq Thursday. Korea Exchange’s corporate review committee decided against a delisting of the company.   
Osstem Implant held an emergency board meeting on Wednesday and decided to buy 30-billion worth of its  shares.
“We will improve the internal stability and accelerate our global business plan after this embezzlement incident,” said CEO Um Tae-kwan.   
Um pledged to increase shareholder value by “implementing various shareholder-friendly policies,” starting with buying back shares. 
Following the embezzlement, Osstem Implant adopted measures to prevent such an incident in the future and improve its business integrity, such as filling more than half of the board members with non-executive directors and establishing a corporate audit committee and an ethical management committee, the company said. It also appointed a compliance officer and set up a committee for non-executive director recommendations. 
Osstem Implant’s sales target for this year is 1 trillion won, up 21.5 percent from last year's 823 billion won, with an operating profit goal of 170 billion won. The company's operating profit was 141.9 billion won in 2021. 

BY SHIN HA-NEE [[e-mail]]

版权声明：所有「牙牙在线」的原创文章，转载须联系授权，并在文首/文末注明来源、作者、微信ID，否则我们将向其追究法律责任。部分文章推送时未能与原作者或公众号平台取得联系。若涉及版权问题，敬请原作者联系我们。

更多阅读：

民营口腔连锁「通策医疗」：管理层的讨论和分析，2021年收入增33%、净利增42%

民营口腔连锁、新三板上市公司「华美牙科」：2021年收入增长约20%，扭亏为盈

民营口腔连锁「奥新全民口腔」：2021年收入1.6亿元、同比增20.8%